Sriram Ryali Biography and Net Worth

Sri Ryali is the chief financial officer for Caribou Biosciences and is responsible for strategic leadership of the company’s corporate finance, accounting, and investor relations and corporate communications functions. Most recently, Sri served as the chief financial officer of Codexis, Inc., a publicly traded enzyme engineering company. Previously, he served as chief financial officer of Eiger BioPharmaceuticals, Inc., then a publicly traded, commercial-stage company. Previously at Aimmune Therapeutics, Inc., Sri held roles of increasing responsibility, most recently as vice president of finance. Earlier in his career, he worked at Onyx Pharmaceuticals, Inc. and Amgen Inc. in finance-related positions of increasing responsibility. Sri earned an MBA from the UCLA Anderson School of Management and a BA from the University of California, Los Angeles, with a double major in economics and microbiology, immunology, and molecular genetics.

What is Sriram Ryali's net worth?: The estimated net worth of Sriram Ryali is at least $27.86 thousand as of January 29th, 2025. Ryali owns 17,360 shares of Caribou Biosciences stock worth more than $27,863 as of August 6th. This net worth approximation does not reflect any other investments that Ryali may own. Learn More about Sriram Ryali's net worth.
How do I contact Sriram Ryali?: The corporate mailing address for Ryali and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Sriram Ryali's contact information.
Has Sriram Ryali been buying or selling shares of Caribou Biosciences?: Sriram Ryali has not been actively trading shares of Caribou Biosciences during the last quarter. Most recently, on Wednesday, January 29th, Sriram Ryali bought 17,360 shares of Caribou Biosciences stock. The stock was acquired at an average cost of $1.42 per share, with a total value of $24,651.20. Following the completion of the transaction, the chief financial officer now directly owns 17,360 shares of the company's stock, valued at $24,651.20. Learn More on Sriram Ryali's trading history.
Who are Caribou Biosciences' active insiders?: Caribou Biosciences' insider roster includes Tina Albertson (Insider), Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Rachel Haurwitz (CEO), Steven Kanner (Insider), Timothy Kelly (CTO), Ruhi Khan (Insider), Barbara McClung (Insider), and Sriram Ryali (CFO). Learn More on Caribou Biosciences' active insiders.
Are insiders buying or selling shares of Caribou Biosciences?: During the last year, insiders at the sold shares 4 times. They sold a total of 18,089 shares worth more than $35,454.44. The most recent insider tranaction occured on February, 24th when CTO Timothy P Kelly sold 3,147 shares worth more than $6,168.12. Insiders at Caribou Biosciences own 8.5% of the company. Learn More about insider trades at Caribou Biosciences.
Information on this page was last updated on 2/24/2026.

Sriram Ryali Insider Trading History at Caribou Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/29/2025	Buy	17,360	$1.42	$24,651.20	17,360

Sriram Ryali Buying and Selling Activity at Caribou Biosciences

Caribou Biosciences Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Today's Range

Now: $1.62

$1.59

$1.68

50 Day Range

MA: $1.76

$1.46

$2.43

2 Week Range

Now: $1.62

$1.38

$3.54

Volume

444,772 shs

Average Volume

1,579,234 shs

Market Capitalization

$160.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38